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ABSTRACT 
In 2015, the American Society of Human Genetics (ASHG) released a position statement 
which recommended minors to defer genetic testing for adult-onset conditions until adulthood. In 
the 2016 DNA Day Essay Contest, high school students were asked to research an adult-onset 
genetic disorder and use it to formulate a stance on whether they agreed or disagreed with the 
position statement. Phase two of this study focused on the essays written about Huntington’s 
Disease (HD). Within the HD essays, 57% chose to defer, 35% chose not to defer, and 8% did 
not clearly state an opinion. Essays were analyzed using a codebook that was established in 
Phase one and the top codes were further analyzed for themes. The top codes that were 
thematically analyzed were “Psychological Risks to Minor”, “No Medical Benefit/Not 
Preventable”, “Necessary to Plan/Prepare”, and “Genetic Testing Variability and Uncertain 
Predictability.” Although many of the essays agreed to defer testing, many students cited similar 
reasons, regardless of their stance. 
Keywords: predictive testing, presymptomatic testing, minors, adolescents, adult onset, 
ethics, perspectives, attitudes, genetic testing, Huntington’s Disease 
BACKGROUND 
 Genetic testing in the pediatric setting is a rare occurrence outside of newborn screening. 
Generally, genetic testing of minors is only done for diagnostic or immediate medical purposes; 
otherwise, most professional organizations recommend that minors postpone testing until 
adulthood. There are arguments in the literature both supporting and discouraging the testing of 
minors for adult-onset conditions, such as Huntington’s Disease.   
 
 
Current Guidelines for the Genetic Testing of Minors 
A number of North American societies for genetics professionals, including the National 
Society of Genetic Counseling (NSGC), the American Society of Human Genetics (ASHG), and 
the American College of Medical Genetics and Genomics (ACMG) have guidelines for genetic 
testing of minors. With regards to predictive testing of minors for adult-onset conditions, the 
professional organizations all acknowledge potential concerns, such as possible stigma, 
discrimination, loss of autonomy, or anxiety; however, they vary slightly in their 
recommendations. The American Academy of Pediatrics (AAP), ACMG, and ASHG take a 
strong stand on the deferral of testing with the exception of medical necessity during 
adolescence, while NSGC is less cut and dried in their recommendation. If a minor is undergoing 
sequencing, a lab may feel an obligation to analyze and interpret the genomic data for pathogenic 
variants for the 59 medically-actionable genes recommended by the ACMG, which are 
responsible for 24 conditions, some of which are adult-onset (Kalia et al., 2017). As a result, 
there was a tension between two ACMG-supported guidelines—minors should postpone 
predictive testing for adult-onset conditions and the requirement to return secondary findings on 
a sequencing result regardless of age (Clayton et al., 2014). However, the ACMG has updated 
their recommendations to give parents the opportunity to opt-out of secondary findings for their 
children, if they wished to do so (Kalia et al., 2017). NSGC recommends that, if possible, testing 
be deferred until a time at which the individual who is being tested has the capacity to 
understand the weight and process the decision to be tested. This recommendation does not bar 
the testing of an adolescent or other minors if conditions warrant it (“National Society of Genetic 
Counselors: Position Statement: Genetic Testing of Minors for Adult-Onset Conditions,” 2017). 
Although ASHG recommends deferring testing for adult-onset conditions until adulthood, they 
recognize the potential for earlier testing in the context of relieving psychosocial distress and 
making life-planning decisions (Botkin et al., 2015). While the professional organization 
guidelines provide a guide for healthcare professionals, it is based on limited data summarizing 
clinical experience and there remains questions to be answered that will require continued 
reevaluation with the growth of genetic testing. 
Consent vs. Assent  
In most settings, the legal age for decision making is 18 years old. However, legal and 
ethical policy guidelines encourage caregivers to help minors take on a greater role in decision-
making regarding their health when they are competent to do so (Botkin et al., 2015). 
Competence has been defined by three main capacities: “(1) to process and communication, (2) 
to reason and deliberate, (3) to develop and sustain moral values” (Botkin et al., 2015). The 
capacity of a child to give consent vs. assent is driven by their cognitive ability. In the United 
States, children can begin being involved in decision-making by age 7 and thus can provide 
“assent” to participate in research from that time on (Botkin et al., 2015). Assent only requires a 
basic understanding of risk and benefit, while consent requires the ability to make independent 
decisions. Consent becomes possible around the time of adolescence when minors have begun to 
connect the present with the future and understand the long-term effects of decision-making to 
some degree. This is thought to be around age 12-14. In adolescence, experts argue, minors are 
still very malleable and can be influenced by a variety of factors including self-image, family 
pressures, and stigmatization. (Botkin et al., 2015). The AAP statement on testing of minors 
asserts that for predictive testing, the assent of the child should be sought and stresses that the 
results of the test are ultimately theirs (Clayton, 2015). 
 
Risks of Testing Minors for Adult-Onset Conditions 
         In the bioethics literature, there are three main arguments against testing minors for adult-
onset conditions: lack of respect for the child’s autonomy and their right not to know, concerns 
about breaching the child’s confidentiality, and the potential psychological harm (Aatre & Day, 
2011; Duncan et al., 2008; Malpas, 2008; Mand, Gillam, Delatycki, & Duncan, 2012). Among 
the possible harms that have been discussed are distress, anxiety, and depression with the return 
of a positive result (Aatre & Day, 2011; Bradbury et al., 2016). Some experts have raised the 
possibility of vulnerable child syndrome and survivor guilt (Aatre & Day, 2011; Bradbury et al., 
2016; Mand et al., 2012). Overall, potential adverse emotional outcomes include altered self-
esteem, feelings of blame, stigma, discrimination, and difficulty forming or maintaining 
relationships with family and peers (Aatre & Day, 2011; Bloch & Hayden, 1990; Bradbury et al., 
2016; Mand et al., 2012; Wade, Wilfond, & Mcbride, 2010). All of these feelings might 
reasonably be expected to tie into the child’s maturity level but, to contrary, Duncan et al. found 
that many of the harms described by adolescents were not much different than those experienced 
by adults (2008). 
Benefits of Testing Minors for Adult-Onset Conditions 
         Counter arguments have been made to refute the idea that testing minors for adult-onset 
conditions is problematic. Parents, it has been pointed out, can be expected to act in their child’s 
best interests (Mand et al., 2012; Rhodes, 2006). Furthermore, adolescents are often more than 
capable of making decisions regarding their own health (Borry, Goffin, NYS, & Dierickx, 2008). 
Rhodes goes on to argue that the issue of confidentiality is moot because parents already bear the 
responsibility of their child and make medical decisions on their behalf (2006). 
         As for psychological harm, Rhodes found in a 2006 study that after a brief period of 
adjustment to the information, there was little to no harm (Rhodes, 2006). The argument for 
testing assumes that testing may be beneficial because it promotes knowledge and a sense of 
control and empowerment in the individual and, in turn, offers them a realistic expectation of 
their prognosis with the condition (Malpas, 2008; Mand et al., 2012). In some studies, children 
who have been tested have been found to have higher self-esteem in the context of both positive 
and negative results (Aatre & Day, 2011; Mand et al., 2012; Rhodes, 2006). Bradbury et al. 
found that girls with a positive BRCA1 or BRCA2 result and family history had higher self-
esteem than those without the family history; this was found to be correlated with lower maternal 
anxiety, strong communication within family, and having prior exposure to the condition (2016). 
Huntington’s Disease 
Huntington’s Disease is an adult-onset neurodegenerative disorder that has an autosomal 
dominant pattern of inheritance. Individuals who carry an expansion of 36 or more CAG 
trinucleotide repeats in one of their HTT genes will inevitably develop severe and progressive 
motor, cognitive, and psychiatric disturbances. Currently, there are no effective treatments for 
HD and the median survival time is 15-18 years after onset, which typically occurs during the 
3rd or 4th decade of life. To date, care remains mainly supportive (Warby, Graham, & Hayden, 
1993). Genetic testing for HD is extremely accurate. Pre-symptomatic testing is accompanied in 
most medical centers by a team-based, pre-test protocol including psychiatric and neurologic 
evaluations and genetic counseling. It is generally not easily available to minors (Huntington’s 
Disease Society of America, 2016; MacLeod et al., 2013).  
One study that included 480 adults who had not previously been clinically diagnosed 
with HD but had either a positive genetic test or family history of the disease found that almost 
half (46 %) of respondents reported genetic discrimination or stigma based on their genetic status 
and/or family history of HD (Erwin et al., 2010). The highest proportion of discrimination and/or 
stigma was described as related to insurance and relationships (Erwin et al., 2010). Within this 
study, they discussed how it is currently not understood to what extent genetic stigma and/or 
discrimination has an impact on daily life decisions. As such, there is little understanding of the 
potential impact that genetic stigma and discrimination could have on minors.  
The Need for Adolescent Opinions 
 Currently, literature on the impact of predictive testing of minors for adult-onset 
conditions is very limited and consists mainly of research and opinion provided by healthcare 
providers and bioethicists. The perspective of the minors themselves is absent from the debate. 
This study is part of an ongoing analysis of the essays from the ASHG 2016 International DNA 
Day essay competition, which provide a unique opportunity to hear from adolescents on their 
opinions on genetic testing of minors for adult-onset conditions. The present study focuses on a 
subgroup of those essays which discuss Huntington’s Disease.   
MATERIALS AND METHODS  
In Phase one of this study, a mixed-methods approach was developed to analyze essays 
written by high school students submitted to ASHG’s annual 2016 International DNA Day Essay 
Contest. The essay prompt for 2016 was as follows: 
“Choose a genetic test that is currently available for a condition or disease that 
does not cause symptoms until adulthood (i.e., an adult-onset condition such as 
hereditary breast cancer). Describe how the test works and how certain the test 
results are. Then, either defend or refute the recommendation below from ASHG’s 
recent position statement on pediatric genetic testing. “Adolescents should be 
encouraged to defer predictive or pre-dispositional testing for adult-onset 
conditions until adulthood because of the complexity of the potential impact of the 
information at formative life stages.” 
The high school students were informed that their submissions might be used for research. Phase 
one of this project received an exemption from the Sarah Lawrence College Institutional Review 
Board (IRB) in April 2016 and Phase two received an exemption from the same body in October 
2017. Approval was also sought and received from the Geisinger Health System IRB in March 
2016. 
All essays were initially categorized based upon demographic information (grade, gender, 
country), which disease the individual chose to write about, and whether they chose to agree with 
the ASHG statement (defer testing), disagree (not defer testing), or did not clearly state at 
opinion (other). A code book was developed with the intention of investigating reasons why 
minors would defer or not defer genetic testing for adult-onset diseases. The final code book 
consisted of 25 universal codes that were used to analyze the essays in the qualitative analysis 
program Atlas.ti (www.atlasti.com). 
Code  Description 
Psychological benefits to 
minor 
Benefits of knowing or not knowing their own genetic 
information 
Psychological risks to minor Risks of knowing or not knowing their own genetic 
information  
Genetic testing accuracy and 
predictability  
High accuracy of genetic testing due to detection rate, 
reliability, validity, predictability, technological accuracy  
Genetic testing variability and 
uncertain predictability 
Limitations of genetic testing due to low detection rate, 
reliability, validity, predictability, technological accuracy 
(low genotype to phenotype predictability) 
Factual genetic/disorder 
information 
Facts about genetics/the disorder that they chose to write 
about 
Incorrect facts Any facts that are used in the essay that are incorrect 
Risks to family  Possible negative effects of knowing or not knowing the 
genetic information would have on family members 
Benefits to family Possible negative effects of knowing or not knowing the 
genetic information would have on family members 
Personal experience with the 
condition 
Mention of personal experiences with the disorder described 
(themselves or family members) that influences their opinion 
on testing or not testing 
Personal experience with 
genetic testing 
Mention of personal experiences with genetic testing 
described (themselves or family members) that influences 
their opinion on testing or not testing 
Medical benefit/prevention Possibility of medical prevention or benefit that comes with 
testing for the condition 
No medical benefit/prevention Lack of medical prevention or benefit that comes with testing 
for the condition 
Disrupts formative years The right to be a child/have a normal adolescence. 
Social risks Negative changes in any social relations such as friends, 
colleagues, and schoolmates 
Social benefits Positive changes in any social relations such as friends, 
colleagues, and schoolmates 
Mature and capable Minor’s ability to adapt, handle, fully process the information 
Immature and incapable Neurological, emotional, and/or social immaturity 
Potential discrimination Any discrimination in career, insurance, social, stigma. 
Necessary to plan/prepare Genetic testing is necessary to plan for future as a minor 
Unnecessary to plan/prepare Genetic testing is unnecessary to plan for future as a minor (at 
this time) 
Advancements in science  Altruism or altruistic intent/contribute to research 
Case-by-case Suggestion to take each genetic testing case individually 
(indicating that there are some instances when it is and is not 
appropriate) 
Loss of autonomy  Child’s inability to provide informed consent. Should not be 
pressured, voluntary. 
Individual’s choice The opinion of the minor should be upheld over anyone else 
Family/parent’s choice  The opinion of the minor/s family/parents should be upheld 
over anyone else 
 
Of the 1241 essays submitted, 77 were discarded as unfit for coding, including those that 
did not address the prompt or focused on a different topic, were illegible or unintelligible, did not 
state an opinion, or misinterpreted the question or ASHG policy.  
In order for the coders in Phase one of the project to reach inter-rater reliability (IRR), 
five essays were coded by each coder separately, and then compared. This process was repeated 
until an IRR ≥ 75% was reached, and then the remaining HBOC, AD, and Lynch Syndrome 
essays were divided evenly between the four group members for coding.  
The most common disorders discussed in these essays were Huntington Disease (HD), 
Alzheimer’s Disease (AD), and Hereditary Breast and Ovarian Cancer (HBOC). In Phase one, all 
essays with an HBOC or Alzheimer’s Disease theme were coded, analyzed, and discussed. All 
essays discussing Lynch syndrome (13 in total) were also thematically coded but not included in 
the final analysis.  
The focus of Phase two of the study was the coding and analysis of themes emerging in 
the essays written about HD. An IRR of 82.9% was established between four new coders in the 
same manner as described above. In addition, five previously coded essays from the Phase one 
data set were blindly coded by each new group member and subsequently compared to one 
another as well as the previous codes in order to establish if IRR between the Phase one and 
Phase two coders. A collective IRR (between the coders from Phase one and two combined) of 
76.5% was established.  
 
Figure 1. The process of reaching inter-rater reliability (IRR) between coders in Phase one 
and two 
A total of 467 HD essays were equally divided among the four group members for 
coding. The Phase one universal codebook was adopted in full with no changes to the 25 codes. 
All essays had been previously uploaded to Atlas.ti and were coded using this program.  
 Upon completion of initial coding of the HD essays, data was downloaded from Atlas.ti 
to Excel spreadsheets. Included in these data sets were totals of top codes used as well as a list of 
the exact quotes used for these codes. Top five codes used were established to be: “Factual 
Genetic/Disorder Information”, “Necessary to Plan/Prepare”, “Genetic Testing Variability and 
Uncertain Predictability”, “No Medical Benefit”, and “Psychological Risks to Minor.” All five of 
these codes, except for “Factual Genetic/Disorder Information”, were further analyzed for 
themes by reading through the quotes pulled from the respective essays. “Factual 
Genetic/Disorder Information” was excluded from the additional analysis for themes because 
this information was required to be included in the essays and offered no further insight into their 
reasoning behind whether they agreed or disagreed with the ASHG recommendation. Each of the 
other main codes were analyzed further for specific themes. Themes were counted and organized 
into tables of their own. All final counts accounted for the number of unique essays that used a 
particular theme within a code. For example, one essay might have used one code three times, 
but only addressed two themes. This essay would be counted twice in the tables, one for each 
theme. The essay was the unit of analysis, and the number of themes per essay was quantified to 
illustrate any thematic similarities or differences between defer and non-defer arguments. 
RESULTS 
 Of the 1241 student essays submitted to the 2016 ASHG DNA Day Essay Contest, 467 
essays were about Huntington’s Disease. Out of these 467 essays, 266 chose to “Defer” testing, 
163 essays chose to “Not Defer” testing, and 38 essays cited “Other” or “None” on testing 
opinion. Table I illustrates how the Huntington’s Disease essays were broken down by testing 
choice. Table II shows the demographics of the 429 “Defer” and “Not Defer” essays, broken 
down by gender and grade level. 
Testing Choice Number of Essays % of Total Essays 
Defer 266 57% 
Not Defer 163 35% 
Other/None 38 8% 
Table I. Testing choices of the 467 Huntington’s Disease essays 
Demographics % that 
Deferred 
% that Not Deferred 
Female 64% 36% 
Male 58% 42% 
9th Grade 63% 37% 
10th Grade 58% 42% 
11th Grade 69% 31% 
12th Grade 59% 41% 
Table II. Demographics of the 429 Huntington’s Disease essays that chose to “Defer” and “Not Defer” testing 
 Table III describes the top five codes utilized in the Huntington’s Disease essays and the 
number of quotes associated with each code. 
Code Number of Quotes 
Factual Genetic/Disorder Information 817 
Psychological Risks to Minor 526 
No Medical Benefit or Prevention 341 
Necessary to Plan and Prepare 340 
Genetic Testing Variability & Uncertain Predictability 191 
Table III. Top five codes used in the Huntington’s Disease essays 
Psychological Risk to Minor 
The code “Psychological Risk to Minor” was used 526 times in essays. This code was 
defined in the codebook as statements that describe an increase in the adolescent’s anxiety, 
depression, apathy, fear, helplessness, devastation, or loss of self-esteem, as well as statements 
about risky behavior, self-harm and suicide. This code was used to describe any psychological 
consequences that may arise due to the decision to pursue or to not pursue genetic testing for 
Huntington’s Disease. The themes present within this code were General psychological risk to 
minor, Anxiety, Depression, Self-harm/suicide, Harm self-esteem, Harm development, Substance 
abuse, Survivor’s guilt, Hopelessness, and Helplessness. “Psychological Risk to Minor” was split 
into the following four testing scenarios: (1) pursuing genetic testing and receiving a positive 
result, (2) pursuing genetic testing and receiving a negative result, (3) pursuing genetic testing in 
general, and (4) not pursuing genetic testing. These scenarios were then subdivided into essays 
that chose to defer or not defer testing. The frequency of use for each theme is displayed in Table 
IV.  
Psychological risk to a minor when receiving a positive genetic testing results for 
Huntington’s Disease was the most commonly discussed scenario, showing up 389 (74.0%) 
times. Of the 389 essays which discussed this topic, 331 (85.1%) of these essays chose to defer 
testing, while 38 (9.8%) chose to not defer, and 20 (5.1%) did not clearly specify. Of the essays 
which chose to defer, the most common themes were Psychological risk to minors in general 
(31.7%), risk for Depression (21.1%), and the risk for Anxiety (19.3%). 
The second most common scenario was the psychological risk to a minor when pursuing 
genetic testing for Huntington’s Disease in general, without specifying the outcome of the 
results. This was discussed 113 (21.5%) times. Out of the 119 times this topic was discussed 92 
(77.3%) chose to defer, 17 (14.3%) chose to not defer and 4 (3.4%) did not specify.  
All but one essay which discussed negative test results and chose to defer (91.7%) used 
the theme Survivor’s guilt.  
Overall, the three most commonly used themes were Psychological risk to minor in 
general (47.8%), risk for Anxiety (20.7%), and risk for Depression (12.0%).   
 
Theme Positive Test Results Negative Test 
Results 
Testing in General Not Testing Total 



















































































































































































0  0  0  0  0  3 
(3.3%
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0 0  0  0  0  6 
(6.5%
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0  0  0  0  1 
(1.1%
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0  0  0  0  0  0  0  0  0  0  4 
(0.8%
) 
Total 331 38 20 12 0 0 92 17 4 2 10 0 526 
Table IV. Psychological Risk to Minors and its Themes 
 
 
Figure 2. Psychological Risks and its Themes 
No Medical Benefit/Not Preventable 
The code “No Medical Benefit/Not Preventable” was defined within the codebook as a 
discussion of the lack of benefit or prevention. This code was used with statements that describe 
no treatments or prevention to stop the development of the disease or to cure the disease and the 
lack of available screening to minors. The essays that were coded as “No Medical Benefit/Not 
Preventable,” were then subcoded for themes. The themes included Ineligible for clinical trials, 
Limited treatment options, No changes in medical intervention as child, No cure, No indication 
of disease course, No indication of disease onset, No prevention, No treatment, Treatment side 
effects, and Treatment can’t slow down /stop illness. Among the essays coded, the themes No 
cure and No treatment were most common (Table V).   
         The theme No Cure was the most common theme in both the “Defer” and “Not Defer” 
essays. In the “Defer” essays, the No cure theme was used 42% of the time and in the “Not 
Defer” essays, it was used 60% of the time. No treatment was the second most common theme 
under the code “No Medical Benefit/Prevention.” In the “Defer” essays, the No treatment theme 
was used 19% of the time and in the “Not Defer” essays it was used 11% of the time.  




Ineligible for clinical trials 3 (1.8%) 0 0 3 (1.2%) 
Limited treatment options 3 (1.8%) 2 (3.5%) 0 5 (2.0%) 
No changes in medical intervention as 
child 
1 (0.5%) 0 0 1 (0.4%) 
No cure 72 
(42%) 
34 (60%) 9 (45%) 115 
(46.5%) 
No indication of disease course 5 (2.9%) 0 0 5 (2.0%) 
No indication of disease onset 6 (3.5%) 1 (1.8%) 0 7 (2.8%) 
No prevention 23 
(14%) 
5 (9%) 1 (5%) 29 (11.7%) 
No treatment 33 
(19%) 
6 (11%) 5 (25%) 44 (17.8%) 
Treatment side effects 1 (0.5%) 1 (1.8%) 0 2 (0.8%) 




8 (14%) 5 (25%) 36 (14.5%) 
Total 170 57 20 247 
Table V. No Medical Benefit and its Themes 
 
Figure 3. No Medical Benefit and its Themes 
Necessary to Plan/Prepare 
The code “Necessary to Plan/Prepare” was defined within the original codebook as 
“genetic testing is necessary to plan for future as a minor.” This code was used with statements 
that describe the necessity of obtaining their genetic information in order to adequately plan and 
prepare for future aspects of one’s life. The quotes that were coded as “Necessary to 
Plan/Prepare,” were then analyzed for themes. The themes that emerged from this code included: 
Making proper financial/emotional arrangements before getting sick, Family 
planning/reproductive purposes, General planning/preparing for one’s future, and Accomplish 
goals/have meaningful life before disease onset. 
The two most common themes for this code are Making proper financial/emotional 
arrangements before sick and Family planning/reproductive purposes. These themes accounted 
for 40% and 38%, respectively, of the 255 essays in which this code was used (including defer, 
not defer, and other/none). The majority of essays expressing the Making proper 
financial/emotional arrangements before sick theme were “Not Defer” essays (72 versus 20 
“Defer” essays). This was similar for the Family planning/reproductive purposes theme, where 
67 were “Not Defer” and 24 were “Defer”. The vast majority of essays using the code 
“Necessary to Plan/Prepare” were “Not Defer” essays (181 of 255 or 70.9%), regardless of the 
theme (Table VI). 
Theme  Defer Not 
Defer 
Other/None Total  
Making proper financial/emotional 





6 (37.5%) 102 
(40%) 




5 (31.3%) 96 
(38%) 






3 (18.8%) 30 
(12%) 
Accomplish goals/meaningful life before 
disease onset 
5 (8.6%) 20 
(11.0%) 
2 (12.5%) 27 
(11%) 
Total  58 181 16 255 
Table VI. Necessary to Plan/Prepare and its Themes 
 
 
Figure 4. Necessary to Plan/Prepare and its Themes 
 
Genetic Testing Variability and Uncertain Predictability 
 
 The code “Genetic Testing Variability and Uncertain Predictability” was defined in the 
original codebook as: “Limitations of genetic testing; detection rate, reliability, validity, 
predictability, technological limitations (unclear genotype to phenotype correlation).” This code 
was used with statements that described the genetic testing for Huntington’s Disease as 
uncertain, inaccurate, or unable to predict the onset or symptoms of the condition. The themes 
within this “Genetic Testing Variability and Uncertain Predictability” code were Intermediate 
range of repeats, Not 100% accurate/certain, Uncertain predictability of symptoms, and 
Inconclusive results.  
 The most common theme was Uncertain predictability of symptoms, which made up 
about 46% of all the essays that used “Genetic Testing Variability and Uncertain Predictability” 
code. The same theme was also the most prevalent in both the “Defer” and “Not Defer” essays 
with 45% and 50% of the essays, respectively. In the “Other/None” essays, the most common 
theme used was Not 100% accurate/certain, accounting for 57% of those essays. Table VII lists 
the proportion of “Defer”, “Not Defer”, and “Other/None” essays that fall under the various 
themes. 
Theme Defer Not 
Defer 
Other/None All 
Intermediate range of repeats 32 (26%) 17 (31%) 1 (14%) 50 (27%) 
Not 100% accurate/certain 36 (29%) 9 (17%) 4 (57%) 49 (26.5%) 
Uncertain predictability of 
symptoms 
56 (45%) 27 (50%) 2 (29%) 85 (46%) 
Inconclusive results 0 1 (2%) 0 1 (0.5%) 
Total 124 54 7 185 
Table VII. Genetic Testing Variability and Uncertain Predictability and its Themes 
 
Figure 5. Genetic Testing Variability and Uncertain Predictability and its Themes 
DISCUSSION 
Psychological Risk to Minor 
Limited research so far has not found an increase in psychological risk with testing; 
however, this was the second most discussed theme in the essays discussing HD in this study 
(Wade, Wilfond & McBride, 2010). Overall, students appear to use potential psychological risks 
as a key deciding factor in their argument whether to defer or not defer testing. 
Some students had concerns regarding the potential psychological risk, as demonstrated 
by one student who stated, “The results of testing positive could have major effects on the 
emotional stability of the adolescent” (Essay 667, Defer), but did not delve into the specifics. 
Other students went further in elaborating details of psychological harm. For example, one 
student stated, “Knowing one's test results at a young age can result in anxiety, behavioral 
issues, depression, lessened self-esteem and independence” (Essay 1236, Defer). Most students 
used the natural history, clinical features and the lack of treatment for HD to identify causes for 
the psychological risk. Students referred to HD resulting in early death as an argument both for 
and against testing. As stated by a few students, “the prospect of a confirmed early death could 
have enormous psychological ramifications on individuals positive for HD” (Essay 456, Defer), 
most often noted as an increase in anxiety and depression, and “would have a devastating effect 
on [a person’s] quality of life” (Essay 204, Defer). 
Students who argued for not deferring testing often also recognized the psychological 
risks that could arise due to a positive result, “The simple knowledge that the disease will one day 
be active can hugely impact one’s life and bring forth many emotional consequences. Learning 
about it at a young age may cause huge amounts of fear, anxiety, depression, stress” (Essay 
1202, Not Defer). Individuals who chose to not defer testing, while they cited psychological risks 
associated with testing, many also considered the potential benefits.   
  Although a majority of essays discussing psychological risk to minors pursuing genetic 
testing for HD had stated concerns with receiving a positive HD test result, some students also 
dove into the possible psychological implications of receiving a negative test result and the risks 
associated with not pursuing testing. Students were able to dissect the complexities associated 
with both testing and not testing for a degenerative neurological disorder. All but one student 
who discussed psychological risk in respect to receiving a negative test result brought up the 
possibility of survivor’s guilt. One student described survivor’s guilt as “feel guilty for escaping 
the disease that other members of the family suffer from” (Essay 956, Not Defer). Another 
student demonstrated the complexities of their thoughts by contrasting these potential risks. “The 
result of the HD test may be enough to push the patient into depression and place a heavy 
burden on them. After disclosure of the results, people were found more likely to succumb to 
depression and hopelessness. Those who believed that their results were going to be normal 
experienced many difficulties after knowing their result was positive. Alternatively, those who 
found that their result was negative also experienced survivor’s guilt if a relative’s result 
happened to be positive” (Essay 879, Defer).   
  Anxiety and Depression were present in both arguments made for and against deferring 
genetic testing. These themes were brought up in the context of eventually knowing one will 
develop HD status from a positive test result as demonstrated by the following statement, 
“Realistically, the frustration and helplessness derived from the idea that the deterioration of 
their lives is inevitable would likely lead to depression and anxiety” (Essay 1153, Defer). Anxiety 
was also brought up in the context of not knowing what the future holds by not pursuing genetic 
testing, “deferring a genetic test for an adolescent suspected of carrying a disease places 
uncertainty on that individual, which results in negative emotional effects such as excessive 
worrying and anxiety” (Essay 1094, Not Defer). Many students acknowledged that regardless of 
if they agreed or disagreed with ASHG’s position statement, there were potential psychological 
consequences.    
No Medical Benefit/Not Preventable 
The most common theme used in all HD essays was No cure. The discussion found in 
essays where students argued to not defer testing for HD commonly discussed potential 
treatment, “There is no cure for Huntington’s Disease (HD) but there are treatments to reduce 
its symptoms” (Essay 636, Not Defer). In the “Not Defer” essays, students often discussed the 
lack of cure, but then commented on the availability of treatments. “Even though a cure has yet 
to be discovered, there are steps that can be taken to slow down the progression of the disease” 
(Essay 1146, Not Defer). This was in contrast to the discussion found in essays where students 
argued to defer testing, the No cure theme was often used in the context of death, “HD is fatal, 
and there is no cure” (Essay 585, Defer). In some of the cases, there appears to be a lack of 
knowledge about the availability of treatment, “As this is a fatal disease with no cure, receiving a 
positive test is sometimes seen as a death sentence” (Essay 387, Defer). Even in situations where 
the students acknowledged the availability of medical treatment, the fatality of the condition was 
discussed in essays where the student encouraged deferral, “There are some medications for 
Huntington’s disease, but, ultimately, none of the medications can completely prevent the 
symptoms or the imminent death caused by the disease” (Essay 498, Defer). This contrast in the 
way in which the No cure theme was used in “Defer” and “Not Defer” essays suggests that there 
are some students who felt that the therapies were good enough to warrant testing, while others 
were either unaware of therapies and/or felt that the current treatment is insufficient at this time 
for them to pursue genetic testing.  
         Another common theme within the code, “No Medical Benefit/Not Preventable,” was 
Treatments can’t slow down/stop illness. This was the second most common theme in essays that 
chose to not defer testing for HD, whereas it was fourth most common theme in essays that chose 
to defer testing for HD. In the “Not Defer” essays, the theme Treatments can’t slow down/stop 
illness was used in a much more hopeful manner, “No treatments of our generation are able to 
alter or slow the effects of Huntington’s disease” (Essay 897, Not Defer). This student was 
discussing the lack of treatment, in the context of the current “generation,” which implied that 
there might be changes in the future generations. Another “Not Defer” essay said, “as of now, 
there is no treatment that can alter the course of Huntington's disease” (Essay 806, Not Defer). 
Several of the students referenced the treatments in the context of current time, implying that 
there is hope for future improvements to treatment, “As of today, there are no treatments that 
have the capability of curing the fatal disease” (Essay 367, Not Defer). This may represent how 
some students showed dispositional optimism with regards to the future of medicine, while 
others focused more on the risks. Some research has found that individuals who are high in 
optimism are actually more knowledgeable about risk factors than those who had less optimism 
(Carver et al., 2014). A student who chose to defer testing wrote, “Maybe someday, when there 
are treatments for HD, adolescents should be tested in hopes of being able to fight the disease 
before it attacks. But currently, there are none” (Essay 1226, Defer). Interestingly, this student 
who wrote in favor of the deferral of testing, recognized that there is some hope from 
improvements in treatment, but they feel that testing should be deferred until such time. In 
comparison, in the essays that chose to defer testing, many of the students used this code in 
conjunction with the psychological risk to minors, “However, since there is currently no way to 
prevent, cure, or slow the progression of this disease, testing a child may cause more harm than 
good, for both the child and the parents” (Essay 480, Defer). Another student wrote, 
“determining early in life that the child will develop HD later on does not benefit them in any 
way since there is no treatment that can reduce the risk or change a child’s outcome of 
developing HD” (Essay 841, Defer). Students who wrote in favor of deferring testing often wrote 
about how there is no benefit, but rather a risk to the child, since there is currently no treatment 
available.  
Necessary to Plan/Prepare 
 The variety in themes that emerged under the “Necessary to Plan/Prepare” code 
illustrated the depth of insight these minors have with regards to their future. The majority of 
writers who discussed this concept chose to argue in favor of not deferring testing until 
adulthood, suggesting that they think the information gained through genetic testing for HD is 
valuable during their teen years. This is a time in their life where they are already planning for 
things, such as starting a family and accomplishing long term goals. Even though these minors 
are children in the eyes of some, they are already beginning to speculate what a future family 
might look like for them and how to best plan for the genetic health of that family, “Also, having 
the understanding of the possibility of developing a hereditary disease would prepare 
adolescents ahead of time of the risk of passing on the faulty HD gene to their own offspring. 
This prior knowledge could assist adolescents, later in life, when making decisions concerning 
conception” (Essay 705, Not Defer).  
In addition to family planning, minors expressed the desire to adapt their life goals and 
financial situation to best suit their future health. Even students who argued overall to defer 
testing still acknowledged its potential benefits in adolescence, “a negative result would provide 
reassurance, whereas a positive result would allow for more realistic goals” (Essay 450, Defer). 
Another writer stated, “Adolescence is in fact a superior time to discover such as disease 
because more time is available for planning, whether social, personal, or especially financial” 
(Essay 609, Not Defer).  
Genetic Testing Variability and Uncertain Predictability 
It is well-known in the medical community that the genetic test for HD is highly accurate, 
and a positive result almost certainly means that an individual will develop symptoms of HD in 
the future. Despite this inevitability, the test cannot predict when the symptoms will begin. 
Interestingly, roughly half of the “Defer” and “Not Defer” essays that used the code “Genetic 
Testing Variability and Uncertain Predictability” discussed Uncertain predictability of 
symptoms. Most of the time, the students talked about how the test cannot predict the age of 
onset, the severity of the symptoms, or the progression of the disease, “However, genetic testing 
cannot determine when the symptoms will develop in their intensity and severity” (Essay 378, 
Not Defer). No one identified this as the main reason why they chose to “Defer” or “Not Defer.” 
It was mainly used as factual information to describe the genetic test for HD. 
The theme Intermediate range of repeats, similar to Uncertain predictability of 
symptoms, was mainly used to describe the genetic test for HD and what it entailed. In this 
theme, individuals talked about how the 36 to 39 repeat range was considered the gray area, 
where it is unknown if someone would be affected in the future. Quotes from this theme often 
also cited the unpredictability of the symptoms, but more in terms of whether or not someone 
would truly be affected, rather than the uncertainty of the onset of symptoms, “There is some 
uncertainty with the HD DNA testing; for example, some individuals with CAG repeats from 36-
39 never develop symptoms for HD, while others develop symptoms” (Essay 1074, Defer). Only 
about half the essays that used this theme also mentioned that getting this uncertain result is rare 
and only happens in about 1% of cases. Interestingly, a couple of essays used this uncertain 
result to determine that the test is not accurate, “Some people with counts between thirty-five and 
forty have developed Huntington’s and others have not, so such a count is considered an 
inconclusive result. This gray area means that the test is not entirely accurate” (Essay 1201, 
Defer). They interpreted test accuracy in terms of sensitivity rather than as a measure of the test 
correctly calling the number of repeats. 
Of the essays that used the code “Genetic Testing Variability and Uncertain 
Predictability,” about 29% of the “Defer” essays and 17% of the “Not Defer” essays cited the 
theme Not 100% accurate/certain. Although the genetic test for HD is highly accurate, many 
essays focused on the fact that the test is not 100% accurate, citing human and technical errors 
that may occur, “This genetic test for HD is 98-99% accurate, leaving one or two percent chance 
of inaccuracy only due to the possible, unavoidable errors that may occur in laboratory 
procedures” (Essay 552, Defer). There might be confusion about the definition of accuracy 
because some essays described how the test is not accurate because it is not truly predictive and 
only provides an increased risk of developing HD, “Several genetic tests can only give a 
possibility for a condition and not full certainty, making them unreliable” (Essay 322, Defer). 
Many of the “Defer” essays that had the theme Not 100% accurate/certain used it as one of their 
reasons to defer testing, “Another example of unnecessary stress due to premature testing is 
worrying despite the possibility that one will not develop Huntington’s at all. Even though the 
test is reliable, it is not 100 percent accurate” (Essay 364, Defer). 
Limitations 
  The ASHG DNA Day essays used in this study were a convenience sample which had a 
few limitations. While many of the essays were submitted from the United States, it is unclear 
whether essays were self-submitted or a teacher assigned this to the entire class and hand-
selected the best ones to submit. As discussed in Phase one of this study, there were disparities in 
the demographics of this data. Females represented 67% of the submissions and although 87% of 
submissions were from the United States, not all states were represented equally and some were 
not represented at all; thus, this was not representative of all adolescents. 
CONCLUSIONS 
 Adolescents were split as to whether or not genetic testing for HD should be deferred 
until adulthood, with a majority favoring deferral. Although they were required to argue for or 
against deferring genetic testing for HD until adulthood, most students discussed similar points, 
regardless of their stance. Many were able to consider their lifestyle, values, and goals in their 
decision-making, but there were occasions when they misunderstood or were not fully aware of 
specific information, such as medical management and test accuracy. This exemplifies the 
importance of genetic counseling in the pre-test protocol to make sure that adolescents are well-
informed and mentally prepared to receive genetic testing results. Although many professional 
organizations recommend the deferral of genetic testing for adult-onset conditions until 
adulthood, there is some flexibility in the timing of testing minors on a case-by-case basis. In 
order to provide assent for testing, adolescent perspectives must be considered to determine 
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